HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
MURDOCH CHILDRENS RESEARCH INSTITUTE (Australia)
Inventor
Samuel, Chrishan
Hewitson, Tim
Abstract
The present invention provides pharmaceutical compositions comprising at least one relaxin polypeptide and at least one ACE inhibitor for use in the treatment of fibrosis and fibrotic diseases and in reducing or preventing the progression of pre-existing fibrosis. The invention also provides methods of treatment using such compositions.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
2.
TAM RECEPTOR LIGANDS, METABOLITES AND PRECURSORS THEREOF IN THE DETECTION AND MODULATION OF INFLAMMATORY NEUROPATHOLOGICAL DISEASE
The present disclosure relates to the use of TAM receptor ligands, metabolites, precursor and binding partners thereof in the field of inflammatory neuropathology. This includes the early diagnosis and monitoring of an inflammatory neuropathology as well as screening for medicaments used in the treatment and prophylaxis of such a condition. The method comprises screening blood fluid from a subject for a TAM receptor ligand, or metabolite, or precursor thereof wherein an altered level of the ligand or its metabolite or precursor relative to a control is indicative of the presence of an inflammatory neuropathological disease or condition or a likelihood of developing the same. Diagnostic kits, high throughput screening assays and therapeutic compositions for inflammatory neuropathies are also taught herein.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
3.
A METHOD AND APPARATUS FOR MIXING MICROLITER FLUID VOLUMES BY APPLICATION OF ACOUSTIC SIGNALS
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australia)
Inventor
Aumann, Timothy Douglas
Boon, Wah Chin
Horne, Malcolm Kenneth
Zhu, Yonggang
Duran, Karolina Petkovic
Manasseh, Richard
Abstract
The present disclosure teaches the facilitation of fluid mixing in microliter volume environments. Enabled herein is enhanced mixing of molecular and cellular participants in a biochemical, chemical or physiological transformation within microliter volume environments. The enhanced mixing of microliter volumes of reactant fluid enables greater efficacy of interaction between the transformation participants in the fluid. The present disclosure teaches the use of limiting amounts of transformation participants in an efficient manner in microliter environments.
B01F 11/02 - Mixing by means of ultrasonic vibrations
B81B 7/04 - Networks or arrays of similar microstructural devices
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
C12M 1/02 - Apparatus for enzymology or microbiology with agitation meansApparatus for enzymology or microbiology with heat exchange means
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
Shabanpoor, Fazel
Hossain, Mohammed Akhter
Bathgate, Ross Alexander David
Wade, John Desmond
Gundlach, Andrew Lawrence
Abstract
The present invention relates to biologically active relaxin polypeptides comprising a relaxin A chain and a B chain derived from a relaxin superfamily member, wherein the A chain comprises no intra-chain disulphide bonds. In particular embodiments the modified polypeptides comprise relaxin-3 derived A and B chains, and truncations of the A and/or B chains from the N-termini and/or C-termini. In particular embodiments the polypeptides of the invention are selective agonists or antagonists of the RXFP3 receptor.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
Gundlach, Andrew Lawrence
Lawrence, Andrew J.
Abstract
The present invention relates to methods for the prevention or inhibition of negative behaviours associated with substance abuse or addiction, such as substance use (self-administration) or substance seeking behaviour, the methods comprising administering to subjects in need thereof an antagonist of a relaxin-3 receptor. In particular embodiments the relaxin-3 receptor is the RXFP3 receptor, and in particular embodiments the antagonist is a modified relaxin polypeptide, optionally a selective antagonist of RXFP3.
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
THE UNIVERSITY OF QUEENSLAND (Australia)
Inventor
Rosengren, Karl, Johan
Haugaard-Kedstrom, Linda Maria
Bathgate, Ross, Alexander, David
Hossain, Mohammed, Akhter
Wade, John, Desmond
Gundlach, Andrew, Lawrence
Lawrence, Andrew, J.
Abstract
The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Methods, compositions and kits based on TAM receptors, or TAM receptor ligands or agonists are provided for detection of neuropathological diseases or determination of their progression. The neural diseases in particular include multiple schlerosis or other inflammatory neural disorders that are characterized by demyelination, oligodendrocyte cytotoxicity and microglial activation. These methods include screening cells of a subject where identification of an elevation of expression of a TAM receptor or a change in expression of a TAM receptor ligand is diagnostic of the disease presence or progression. In addition treatment of subjects with such neuropathological diseases by administering TAM receptor ligands (such as GAS 6 or Protein S) or by administering agonists such as antibodies specific for the TAM receptors; Axl, Mer or Tyro3 is described.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The specification relates to methods for treating a neurodegenerative disease such as multiple sclerosis by administering to a subject in need an EphA4 antagonist or an EphA4 ligand antagonist. The antagonist may be a soluble EphA4 or EphA4-binding ephrin or a functional variant thereof such as an EphA4-Fc or an ephrin A5-Fc. The antagonist may be an antibody or an antigen binding antibody fragment, a nucleic acid, polypeptide, peptide, or organic molecule that binds to EphA4 or an EphA4-ligand or a nucleic acid encoding same and downregulates its activity.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
This invention relates to a method of assaying a compound for its ability to modulate an ion channel or receptor type, the method comprising: a) providing a dynamic clamp in electrical contact with a biological cell (or part thereof) in which one or more ion channel or receptor types for providing a waveform are functional and in which one or more ion channel or receptor types for providing a waveform are either not present or not functional; b) causing the dynamic clamp to apply a signal simulating the function of at least one of the one or more ion channel or receptor types that are either not present or not functional in the biological cell (or part thereof) based on modulation of the ion channel or receptor types that are functional in the biological cell (or part thereof) to thereby provide the waveform at the biological cell (or part thereof); c) exposing at least one of the one or more functional ion channel or receptor types to a compound; and d) detecting modulation of the waveform at the biological cell (or part thereof), wherein modulation of the waveform is indicative of a compound that modulates the at least one functional ion channel or receptor types.
The present invention is generally directed to the field of neurological therapy. More particularly, the present invention contemplates therapeutic protocols for neurological conditions associated with dopamine deficiency including pharmaceutical compositions for use in such therapeutic protocols.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH (Australia)
Inventor
Chai, Siew Yeen
Parker, Michael, William
Albiston, Anthony, Lloyd
Mendelsohn, Frederick, A. O.
Watson, Keith, Geoffrey
Abstract
The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
12.
CHIMERIC RELAXIN POLYPEPTIDES COMPRISING AN A AND B CHAIN DERIVED FROM DIFFERENT RELAXIN FAMILY PEPTIDES
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
Bathgate, Ross, Alexander, David,
Hossain, Mohammed, Akhter
Samuel, Chrishan, Surendran
Wade, John, Desmond
Tregear, Geoffrey, W
Abstract
Modified relaxin polypeptides are disclosed wherein the B chain comprises the core sequence CGRxxxRxxI/VxxCG (SEQ ID NO: 1), specifically KLCGRELVRAQIAIC. Chimeric polypeptides comprising a B chain with the core sequence CGRxxxRxxFVxxCG (SEQ ID NO: 1) and an A chain from a heterologous relaxin family peptide are also disclosed. Specifically, chimeric polypeptides comprising a B chain from relaxin-2, and an A chain from relaxin- 1, relaxin-3, insulin, IGF-I, IGF-II, INSL3, INSL4, INSL5 or INSL6, are disclosed.
The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated.
C07C 217/18 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
C07C 217/16 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
C07C 217/20 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
C07D 213/68 - One oxygen atom attached in position 4
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
Kilpatrick, Trevor
Butzkueven, Helmut
Perreau, Victoria
Soo, Pik Ying
Abstract
The present invention relates generally to a method for the treatment and prophylaxis of neurodegenerative diseases and conditions. More particularly, the present invention contemplates the treatment or prophylaxis of neurological conditions involving oligodendrocyte cytotoxicity or cell cycle arrest, demyelination and/or axonal or neuronal degeneration. Agents, medicaments and pharmaceutical compositions useful in the treatment and prophylaxis of neurodegenerative conditions and disorders also form part of the present invention.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A display system, including one or more display modules configured to generate display data for generating a visual representation of a sequence of nucleotides and one or more variations of the sequence. Locations of the nucleotides along the sequence are represented by corresponding locations along a first spatial direction, with each variation of a nucleotide and the corresponding nucleotide being represented by corresponding symbols aligned with a corresponding one of the locations.
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
May, Clive, N
Bellomo, Rinaldo
Abstract
The present invention relates generally to a method of treatment and in particular a method of treating a subject exhibiting symptoms of kidney failure or are at risk of developing same. Even more particularly, the present invention provides a method of treating kidney failure or reducing the risk of developing kidney failure in a subject such as following or during or prior to sepsis or a related condition including severe sepsis, septic shock and the systemic inflammatory response syndrome or any state of systemic or renal vasodilatation with low blood pressure and a high cardiac output with kidney failure, such as liver disease with associated kidney failure or kidney failure after cardiopulmonary bypass in patients in whom the systemic inflammatory syndrome which follows such cardiopulmonary bypass is associated with a high cardiac output and systemic or renal vasodilatation or kidney failure in other conditions which lead to the systemic inflammatory response syndrome with systemic or renal vasodilatation such as major trauma, major surgery and similar states which can induce the aforementioned systemic inflammatory response syndrome.
HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (Australia)
Inventor
Tan, Seong-Seng
Kumar, Sharad
Abstract
Treatment, detection and monitoring of disease of the nervous system, especially trauma or hypoxia, in particular in the central nervous system and the eye by up-regulation or increasing levels of Ndfipl (also known as Nedd4-WW Domain Binding Protein 5 or N4WBP5). Prophylaxis of such conditions in pre-term infants, coronary artery bypass graft, chemotherapy, tumour irradiation and other patients.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/00 - Drugs for disorders of the nervous system
patents